Novavax Raises Outlook, Nuvaxovid Sales Expected to Hit $610M

Novavax reported Q2 2025 sales of $239.24 million, beating the consensus of $156.29 million. The company completed the transition of Nuvaxovid commercial leadership in the US to Sanofi for the 2025-2026 COVID-19 vaccination season. Licensing, royalties, and other revenue included a $175 million milestone earned related to the Nuvaxovid BLA approval. Novavax raises FY25 sales guidance to $1 billion-$1.05 billion and expects Nuvaxovid product sales of $610 million.

Title: Novavax Reports Strong Q2 2025 Financial Results; Raises FY25 Sales Guidance

Novavax, Inc. (Nasdaq: NVAX) has reported robust financial results for the second quarter of 2025, with total revenue of $239 million, exceeding the consensus estimate of $156.29 million. The company achieved this milestone despite a challenging market environment, driven primarily by the success of its COVID-19 vaccine, Nuvaxovid™.

The quarter was marked by several significant achievements. Novavax received FDA Biologics License Application (BLA) approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S. This approval triggered a $175 million milestone payment from Sanofi, one of Novavax's key partners. Additionally, Novavax completed the transition of Nuvaxovid™ commercial leadership in the U.S. to Sanofi for the 2025-2026 COVID-19 vaccination season. This strategic move aligns with the company's ongoing efforts to enhance its partnerships and leverage its technology platform.

Novavax also reported positive data from its COVID-19-Influenza-Combination (CIC) and stand-alone influenza vaccine candidates in a Phase 3 trial. The results showed robust immune responses, with new T-cell response data indicating the potential for an increased duration of protection compared to the comparator Fluzone HD arm. These promising results are expected to inform future registrational Phase 3 programs and attract potential business partners.

The company's licensing, royalties, and other revenue totaled $229 million in the second quarter, primarily driven by the $175 million milestone earned from the Nuvaxovid™ BLA approval. This milestone payment, combined with the transition of commercial leadership to Sanofi, has significantly contributed to Novavax's financial performance.

For the full year 2025, Novavax has raised its sales guidance to $1 billion to $1.05 billion, with Nuvaxovid™ product sales expected to reach $610 million. The company anticipates that the transition of commercial leadership to Sanofi will allow it to focus more on research and development, leveraging its technology platform and pipeline to forge additional partnerships.

In summary, Novavax's strong Q2 2025 financial results are a testament to the company's strategic priorities and successful execution. With promising data from its influenza vaccine candidates and a robust pipeline, Novavax is well-positioned to continue its growth trajectory in the coming quarters.

References
[1] https://ir.novavax.com/press-releases/2025-08-06-Novavax-Reports-Second-Quarter-2025-Financial-Results-and-Operational-Highlights